Washington Trust Advisors’s Haemonetics HAE Stock Holding History

Washington Trust Advisors’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-163	Closed	-$7.95K	–	629
2025 Q3	$7.95K	Buy	163 +34	+26%	+$2.1K	﹤0.01%	558
2025 Q2	$9.63K	Hold	129	–	–	﹤0.01%	481
2025 Q1	$8.2K	Buy	129 +27	+26%	+$1.84K	﹤0.01%	493
2024 Q4	$7.96K	Hold	102	–	–	﹤0.01%	509
2024 Q3	$8.2K	Hold	102	–	–	﹤0.01%	507
2024 Q2	$8.44K	Hold	102	–	–	﹤0.01%	486
2024 Q1	$8.71K	Hold	102	–	–	﹤0.01%	498
2023 Q4	$8.72K	Hold	102	–	–	﹤0.01%	503
2023 Q3	$9.14K	Hold	102	–	–	﹤0.01%	476
2023 Q2	$8.69K	Hold	102	–	–	﹤0.01%	480
2023 Q1	$8.44K	Buy	102 +11	+12%	+$890	﹤0.01%	523
2022 Q4	$7.16K	Hold	91	–	–	﹤0.01%	544
2022 Q3	$7K	Hold	91	–	–	﹤0.01%	649
2022 Q2	$6K	Hold	91	–	–	﹤0.01%	711
2022 Q1	$6K	Hold	91	–	–	﹤0.01%	785
2021 Q4	$5K	Buy	+91	New	+$5.54K	﹤0.01%	849

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Washington Trust Advisors's HAE Position: Q4 2025 in Review

Washington Trust Advisors sold out of Haemonetics (HAE) in Q4 2025, closing a stake of 163 shares — an estimated $7.95K sold.

Washington Trust Advisors first reported a position in HAE in Q4 2021 and held it in 16 quarters. The position peaked at $9.63K in Q2 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q4 2025.

Washington Trust Advisors reported no remaining Haemonetics position as of Q4 2025 after selling out during the quarter.
Washington Trust Advisors sold 163 Haemonetics shares in Q4 2025, an estimated $7.95K.
Washington Trust Advisors first reported a position in Haemonetics in Q4 2021 and held it in 16 quarters.
Washington Trust Advisors's Haemonetics position peaked at $9.63K in Q2 2025.
329 funds tracked by Wall St. Rank held Haemonetics as of Q4 2025.

Based on Washington Trust Advisors's 13F filing for Q4 2025, filed 3 Feb 2026.